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CASE REPORT
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ABSTRACT

Introduction Pancreatic neuroendocrine tumors are slow-growing tumors that account for 1-2% of all pancreatic malignancies. Enucleation
of low-grade pancreatic neuroendocrine tumors has the advantage of avoiding short and long-term morbidities related to formal resections;
however, it carries a risk of significant post-operative pancreatic fistula, especially if the tumor is close to the main pancreatic duct. We have
recently started using intra-operative ERCP to facilitate enucleation of pNETs ≤ 3 mm from MPD. This technique has not previously been
described in the literature. Methods Intraoperative ERCP is considered for patients with pNETs ≤ 3 mm from main pancreatic duct who are
being considered for enucleation. Intraoperative pancreatography is performed after enucleation, to assess for extravasation of contrast
from main pancreatic duct or major side branches at the site of tumor excision. If no extravasation is noted, a pancreatic stent is deployed,
and the procedure is terminated. Significant contrast extravasation on pancreatogram is considered an indicator for the development
of significant post-operative pancreatic fistula, and the procedure needs to be converted to a formal pancreatic resection. Results We
described the steps of the technique, accompanied by images from a patient case. A treatment algorithm is provided detailing a step-bystep approach in patients considered for ERCP assisted enucleation. Conclusion The described technique of ERCP assisted enucleation
allows safe resection of pancreatic neuroendocrine tumors ≤ 3 mm from main pancreatic duct through assessment of main pancreatic duct
integrity, decreasing the risk of significant post-operative pancreatic fistula, and avoiding the morbidity of major pancreatic resections.
Received July 15th, 2019 - Accepted October 2nd, 2019
Keywords Cholangiopancreatography; Endoscopic Retrograde;
Neuroendocrine Tumors; Pancreatectomy; Pancreatic Fistula;
Pancreatic Neoplasms
Abbreviations: POPF post-operative pancreatic fistula; pNETs
pancreatic neuroendocrine tumors; MPD main pancreatic
duct; ERCP endoscopic retrograde cholangio-pancreatography;
CP central pancreatectomy; DP distal pancreatectomy; PD
pancreaticoduodenectomy; IOUS: intraoperative ultrasonography;
EUS endoscopic ultrasound; MRI magnetic resonance imaging; EAE
ERCP assisted enucleation; VHL Von Hippel-Lindau disease; ISGPF
international study group for pancreatic fistula; MEN-I multiple
endocrine neoplasia type-1
Correspondence Maria B Doyle
Division of Transplant Surgery, Department of Surgery
Washington University School of Medicine
4921 Parkview Place, Suite C, 8th Floor
St Louis, Missouri 63110, United States
Tel +314-362-2820
Fax +314-362-4197
E-mail doylem@wustl.edu

INTRODUCTION
Pancreatic
Neuroendocrine
Tumors
(pNETs)
are rare, and account for 1-2% of all pancreatic
malignancies. PNETs are usually indolent but can often
have unpredictable biologic behavior with potential for
malignant transformation. Additionally, pNETs can often
be associated with inherited syndromes such as Multiple
Endocrine Neoplasia type 1 (MEN-1) and Von HippelLindau disease (VHL), which can present at a younger
age with multi-centric pancreatic lesions, adding further
complexity to treatment decision making[1, 2, 3].
Surgical resection of pNETs remains the only curative
treatment option and is regarded as the standard of
care even in some cases with advanced disease. Surgical
options include enucleation or standard pancreatic
resections, such as Pancreaticoduodenectomy (PD),
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Central Pancreatectomy (CP) or Distal Pancreatectomy
(DP). Enucleation has the advantage of parenchymal
preservation with minimal chance of endocrine or
exocrine pancreatic insufficiency - features that make it
an attractive option for younger patients with indolent
pNETs, in whom one might want to avoid both short and
long-term morbidity of a major pancreatic resection.
However, any benefit that can be gained from enucleation
must be weighed against the risk of Post-Operative
Pancreatic Fistula (POPF), especially for tumors close to
the Main Pancreatic Duct (MPD) (≤ 3 mm distance), due
to increased risk of inadvertent injury to MPD or major
side branch [1, 2, 3, 4, 5, 6, 7]. In fact, many surgeons now
consider enucleation a relative contraindication for pNETs
close to the MPD, choosing instead to proceed with more
standard resections such as PD, CP or DP [1, 3, 4, 5, 6, 7].
In this paper we describe our approach of ERCP Assisted
Enucleation (EAE) for deep pNETs (≤ 3 mm from the MPD) as
a technique to increase safety of the procedure, by assessing
for integrity of MPD and early identification of patients at
high risk for development of POPF after enucleation [5, 6, 7].

METHODS AND TECHNIQUE
Patient Selection

Our technique of EAE is reserved for patients with
pNETs that are ≤ 3 mm from MPD and who are otherwise
candidates for enucleation based on tumor size and type.

parenchyma or if there is a concern for the integrity of
MPD at conclusion of tumor enucleation.

RESULTS

Figure 1 shows a Magnetic Resonance Imaging (MRI)
of a 17-year-old girl with MEN-I syndrome who was found
to have a 1.7 cm insulinoma in the head of the pancreas
after a work up for recurrent symptomatic hypoglycemia.
She was managed using EAE technique described
above. Figure 2 shows the appearance of the tumor on
Endoscopic Ultrasound (EUS). The MPD cannot be seen
in this image but was measured to be approximately 2
mm from the deep tumor surface. The tumor was deep
in the parenchyma and was enucleated successfully after
identification with intraoperative ultrasound (Figure 3).
ERCP obtained in the operating room showed an intact MPD
without any significant extravasation at the enucleation
site. Pancreatic stent was deployed due to depth of tumor,
and the very close proximity to MPD. A surgical drain was
left in the vicinity of enucleation site. The patient had an
uneventful post-operative recovery without development
of pancreatitis or significant POPF. She has continued to do
well until the most recent follow-up.

Operative Technique

The surgery can be performed as an open surgery or
laparoscopically, depending on the location of tumor,
patient characteristics and the experience of the surgeon.
After general exploration, lesser sac is entered, and
pancreas exposed. Intra-operative ultrasound is utilized
to assess the pancreas, identify the tumor and re-measure
distance of the pNET from the MPD. The tumor is then
enucleated using standard surgical techniques. Care
should be taken on deeper dissection to stay close to the
tumor in order to avoid inadvertent injury to the MPD.
After enucleation, the pancreatic parenchyma is carefully
inspected. In absence of any obvious injury to the MPD,
an on-table ERCP is performed. On ERCP images, careful
attention should be given to any evidence of contrast
extravasation from MPD or major side branch in the area
of enucleation. If no leakage is apparent, a surgical drain
is left in the vicinity of surgery, and the procedure is
terminated. A PD stent should be placed to reduce the risk
of post-ERCP pancreatitis, and for the treatment of small
leaks, particularly following enucleation of deeper tumors,
which may not be readily apparent on intraoperative
pancreatogram. If the pancreatogram indicates significant
contrast extravasation from the MPD or major side branch
at the time of pancreatogram, this is taken as an indicator
for the development of significant POPF, and the surgery
is converted to a standard pancreatic resection (PD, CP
or DP) depending on the location of pNET. Intraoperative
ERCP can also be considered for enucleation of pNETs>3
mm from the MPD if they are located deep in the pancreatic

Figure 1. MRI showing a 1.7 cm pNET (insulinoma) in head of the
pancreas (red circle) in a 17-year-old girl with MEN-I syndrome and
recurrent symptomatic hypoglycemia.

Figure 2. EUS confirming a 1.7 cm pNET in the head of pancreas (red
circle), approximately 2 mm from the MPD (not seen in this image).
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Figure 3. Intraoperative image after enucleation. Approximately 2 × 2 cm
defect in head of pancreas after enucleation of pNET (yellow circle).
PH=pancreatic head; PB=pancreatic body; D=duodenum, black
hyphenated line showing outline of pancreas, white hyphenated line
tracing duodenal C-loop.

DISCUSSION

PNETs are rare, usually well differentiated, and if
malignant, carry a better prognosis than pancreatic
adenocarcinoma [1]. These tumors are usually sporadic;
however about 10-15% are associated with inherited
genetic disorders such as MEN-1 and VHL [2, 3].

Surgery is the mainstay of treatment of patients with
pNETs, and is indicated to achieve cure, control hormone
hypersecretion, alleviate tumor related local compressive
symptoms, and for palliation purposes in patients
with advanced disease [2, 3]. Surgical options include
enucleation of the tumor with parenchymal preservation,
or standard pancreatic resections (PD, CP or DP) [1,
4, 5]. pNETs<2 cm in size have a very low incidence of
malignancy (6%) which makes enucleation an extremely
attractive option for symptomatic and/or functional
pNETS<2 cm [2]. Enucleation has the advantage of being
less invasive than standard resections with a low (2-5%)
risk of endocrine or exocrine insufficiency compared to
a much higher risk of pancreatic insufficiency seen after
PD, CP or DP, which approaches 50% in some studies [3,
4, 5, 6, 8, 9]. Additionally, pancreatic enucleation results
in less intraoperative blood loss, decreased length of
surgery, and shorter hospital stay when compared
to standard resections [5]. However, enucleation can
lead to disruption of the main pancreatic duct or major
branches manifesting as post-operative pancreatic fistula
(POPF), which can significantly contribute to procedural
morbidity. POPF rates after enucleation vary from 20-67%
and can also range in severity from clinically insignificant
(International Study Group for Pancreatic Fistula [ISGPF]
grade A) to clinically significant (ISGPF grades B & C) [2,
6, 7, 10], which might require additional procedures and
prolonged hospitalization. Many studies have extensively
looked at the risk of POPF after enucleation and have
identified tumor size>3 cm, and distance of ≤ 3 mm from
the pancreatic duct as risk factors for clinically significant
POPF[2, 6, 7, 9]. Some studies have also shown a higher
incidence of POPF after enucleation in patients with

hereditary syndromes, especially MEN-1. Consequently,
many surgeons now consider pNETs ≤ 3 mm from MPD as
a contraindication to enucleation. Preoperative imaging
with CT, MRI/MRCP and Endoscopic Ultrasound (EUS) can
provide valuable information on both the size of the tumor
and its relationship with the main pancreatic duct and use
of intraoperative ultrasound at time of surgery can provide
valuable real time information on orientation with MPD
in borderline cases [3, 6]. However, once enucleation is
started, there is no reliable way to diagnose injury to MPD or
major side branch other than visual confirmation of leaking
pancreatic fluid from disrupted duct. This is often difficult,
especially in lesions deep in the pancreatic head due to
bleeding and cautery eschar (Figure 3). A missed injury to
MPD can be catastrophic and lead to significant morbidity
post-operatively possibly requiring additional procedures.
We believe that in such situations, our described technique
of EAE can help identify any significant pancreatic leak at
time of enucleation providing valuable information that
can help guide further treatment. If a significant leak is
appreciated, then one can proceed with standard resection
(PD for head lesions or DP for lesions of the body and tail)
and potentially save the patient from morbidity related
to clinically significant POPF. If a leak is not seen, then
surgical site can be drained externally, and procedure
terminated with close post-operative follow up of drain
output. Pancreatic stent is deployed after ERCP to reduce
risk of post ERCP pancreatitis and to treat small pancreatic
leaks that may not have been seen on pancreatogram. This
approach has been summarized in Figure 4, in the form of
a treatment strategy algorithm.
The described patient had a highly symptomatic
insulinoma in the head of the pancreas in close proximity
to the MPD. Where everyone agreed that surgery was
required, there was a difference in opinion regarding the
choice of treatment. Given close proximity of the tumor
to the MPD, it would have been reasonable to proceed
with a pancreatoduodenectomy however we were
hesitant in subjecting a 17 year-old girl with an indolent
pNET to potential long and short-term complications
of major pancreatic resection. Use of EAE allowed for
a safe enucleation and potentially avoided the risk of
development of significant POPF. However, the potential
benefit of EAE must be weighed against the small but real
risk of post ERCP pancreatitis. Also arranging ERCP at time
of surgery can present logistical challenges that may need
to be addressed well in advance.

CONCLUSION

The described technique of EAE can be a viable
treatment option for some patients with pNETs in close
proximity to the MPD. It can potentially increase the
safety of the procedure by earlier assessment of integrity
of the MPD, decreasing risk of development of significant
POPF and avoiding the morbidity associated with major
pancreatic resections (PD, CP or DP). Additional studies
are required before efficacy of EAE in management of
pNETs can be clearly established.
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Figure 4. Treatment algorithm for patients with pNET being considered for ERCP assisted enucleation.
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